Stephen Munk

Dr. Munk is experienced in drug discovery, development, and manufacturing both as a scientist and as a manager. He was the CEO and President of Ash Stevens Inc., a full service Active Pharmaceutical Ingredient (API) development and manufacturing organization. From 1997-2017 Ash Stevens received twelve FDA approvals to manufacture innovator drug substances under his leadership. These approvals include the oncology drugs bortezomib (Velcade), busulfan (Busulfex), clofarabine (Clolar), and 5- azacitidine (Vidaza), ponatinib (Iclusig) and ixazomib (Ninlaro). Ash Stevens received six NIH research contracts under his leadership including four competing contract renewals. Prior to joining Ash Stevens in 1997, Steve worked at Allergan, Inc. initially as a medicinal chemist and subsequently, the co-team leader of the adrenergic drug discovery team.

Steve’s work has been summarized in a number of publications and patents. He is a co-author of the 2016 book - Managing the Drug Discovery Process: How to Make It More Efficient and Cost-Effective. Additionally, he have served as an Adjunct Professor of Chemistry at Wayne State University and on the Henry Ford Community College Biotechnology Advisory Board. Steve has also served on the Steering Committee of the Chemistry in Cancer Research Working Group of the American Association for Cancer Research (CICR-AACR; 2008-2010; 2011-2013; Chairman, 2014), the Board of Directors of MichBio (2008 - 2014; Chairman 2010 - 2014), the Michigan Biotechnology Innovation Organization (BIO) affiliate. He received his PhD in Organic Chemistry from the University of California, Berkeley.